Northwestern University

Cour Pharmaceuticals Development Company, Inc.

Tolera Therapeutics, Inc.

University of Michigan

Oncour Pharma, Inc.

Daniel R Getts

Lonnie D Shea

Stephen D Miller

Jonathan Woon Teck Yap

Derrick Mccarthy

Derrick McCarthy

James J Herrmann

John J Puisis

Frank J Fokta

Ryan Pearson

Rachael Terry

Nicholas King

John Puisis

Frank Fokta

James Herrmann

Jonathan Woon Yap

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Peptide conjugated particles

The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).

Covalent polymer-antigen conjugated particles

The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.

Process for the preparation of tolerizing immune-modulating particles

Peptide conjugated particles for the treatment of inflammation

The presently claimed invention relates to methods of reducing the duration or severity of an inflammatory immune response. In embodiments, the method comprises administering poly (lactic acid) (PLA) particles, poly (glycolic acid) (PGA) particles, poly (lactic-co-glycolic acid) (PLGA) particles, or combinations thereof; wherein said particles are modified to contain one or more carboxyl groups on the particle's surface. In embodiments, the particles do not comprise therapeutically active ingredients.

Modified immune-modulating particles

The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Peptide conjugated particles for the treatment of allergy

The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.

Immune-modifying nanoparticles for the treatment of inflammatory diseases

Growing community of inventors

Northbrook, IL, United States of America

Daniel R Getts